We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetically Engineered Tobacco Plants Manufacture Antimalaria Drug

By LabMedica International staff writers
Posted on 02 Jan 2012
Print article
A line of genetically engineered tobacco plants has been developed that carry all the genes required to encode the entire biochemical pathway necessary for producing the potent, but expensive to produce, antimalarial drug artemisinin.

Artemisinin, a natural compound from Artemisia annua (sweet wormwood) plants, is highly effective against drug-resistant malaria, but low-cost artemisinin-based drugs are lacking because of the high cost of obtaining the natural or chemically synthesized compound.

In seeking a way to produce a low-cost version of artemisinin, investigators at the Hebrew University of Jerusalem (Israel) turned to the tobacco plant. Tobacco has high biomass and grows rapidly, so a suitably modified version would be able to produce large quantities of the drug at low cost.

A recent paper in the December 8, 2011, online edition of the journal Nature Biotechnology reported that such a genetically modified tobacco plant was now available. The authors described the creation of transgenic plants that expressed five plant- and yeast-derived genes involved in the mevalonate and artemisinin pathways, all expressed from a single vector. This study demonstrated that artemisinin can be fully biosynthesized in a heterologous (that is, other than A. annua) plant system. Although the artemisinin levels that were generated in transgenic tobacco were currently lower than those in A. annua, this experimental platform may lead to the design of new routes for the drug's commercial production in heterologous plant systems.

This invention has been patented by Yissum (Jerusalem, Israel), the technology transfer arm of the Hebrew University of Jerusalem, which is now seeking a partner for its further development.

Yaacov Michlin, CEO of Yissum said, “This technology provides, for the first time, the opportunity for manufacturing affordable artemisinin by using tobacco plants. We hope that this invention will eventually help control this prevalent disease, for the benefit of many millions of people around the globe, and in particular in the developing world.”

Related Links:

Hebrew University of Jerusalem
Yissum

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.